Limitations in the clinical usefulness of single-dose pharmacokinetic studies of drugs and a bayesian approach for the estimation of kinetic parameters.
This review presents several clinical examples indicating that physiological changes in the body dependent and/or independent of developmental age, genetic polymorphisms, different disease states, acute and/or chronic inflammations, and physicochemical properties of drugs as well as some environmental factors, such as viral infections, may exert a significant effect on the first-time assessment of kinetic parameters of drug absorption, disposition, metabolism, and excretion after a single-dose administration in children and adults. The available pharmacokinetic data in the literature suggest that one must be cautious in interpretation and practical use of pharmacokinetic variables derived from either single-dose studies or bayesian methods, especially in a pediatric population.
Prandota
Joseph
J
Faculty of Medicine and Dentistry, University Medical School, Bartla 5 Str., 51-618 Wroclaw, Poland. Jzef854735@pharmanet.com
D000328:Adult; D001499:Bayes Theorem; D002648:Child; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000378:metabolism; D003863:Depression / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004764:Enterohepatic Circulation; D019450:Genes, MDR; D006801:Humans; D007231:Infant, Newborn; D007249:Inflammation / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000378:metabolism*; D010599:Pharmacokinetics; D011110:Polymorphism, Genetic; D012107:Research Design; D014777:Virus Diseases / Q000378:metabolism
D004364:Pharmaceutical Preparations